Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC-Reference-Cited by-同舟云学术

Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

Published:2024-09-12 Issue:1 Volume:10 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Im Seock-Ah^ORCID,Cortes Javier^ORCID,Cescon David W.^ORCID,Yusof Mastura Md,Iwata Hiroji,Masuda Norikazu^ORCID,Takano Toshimi^ORCID,Huang Chiun-Sheng^ORCID,Chung Chi-Feng,Tsugawa Koichiro,Park Yeon Hee^ORCID,Matsumoto Koji^ORCID,Inoue Kenichi,Kwong Ava^ORCID,Loi Sherene^ORCID,Fu Wei,Pan Wilbur^ORCID,Karantza Vassiliki,Rugo Hope S.^ORCID,Schmid Peter

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41523-024-00679-7.pdf

Reference34 articles.

1. Alcantara, V. S., Lim, G. H., Lim, S. H., Sultana, R. & Lee, J. A. Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia. J. Surg. Oncol. 115, 523–537 (2017).

2. Kulkarni, A. et al. Meta-analysis of prevalence of triple-negative breast cancer and its clinical features at incidence in Indian patients with breast cancer. JCO Glob. Oncol. 6, 1052–1062 (2020).

3. Boyle, P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann. Oncol. 23, vi7–12 (2012).

4. Lin, C. H. et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J. Natl. Cancer Inst. 111, 1298–1306 (2019).

5. Loi, S. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544–1550 (2014).